MindMed FY2022 net loss $56.8M; cash $142.1M; key MM-120 data readouts expected late 2023

Definium Therapeutics, Inc.

Net loss of $56.8M, improved from $93.0M in FY2021; no revenue (clinical-stage biopharma).
Cash and equivalents $142.1M vs $133.5M; cash runway into first half 2025.
R&D expenses $36.2M (up $1.4M); G&A $30.2M (down $28.9M, largely due to lower stock comp).
Phase 2b MM-120 GAD top-line data and Phase 2a MM-120 ADHD data both expected late 2023.
First clinical trial of MM-402 (R-MDMA for autism) planned for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Definium Therapeutics, Inc. updated its the full-year ended December 31, 2022 guidance (reaffirmed).

Period: the full-year ended December 31, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported its financial results for the full-year ended December 31, 2022

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.